GlassScriptPhysician profile
Janet L Eichholz
NPI 1689829590
$6,045.13
in general payments reported to CMS, 2019-2025
30 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,485 · 2020: $572 · 2021: $393 · 2022: $465 · 2023: $568 · 2024: $418 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,130.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,524.16 | 2019-2023 | Pressurewire, Mini Trek, Aveir |
| Pfizer INC. | $272.02 | 2019-2025 | |
| Abiomed | $251.70 | 2019-2020 | |
| Philips North America LLC | $248.36 | 2022-2024 | (Ck4) Mcot |
| Atricure, INC. | $234.93 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.91 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $163.66 | 2021-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $156.57 | 2019-2024 | Farxiga |
| Janssen Pharmaceuticals, INC | $131.23 | 2019-2022 | |
| Silk Road Medical, INC. | $122.85 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Medtronic, INC. | $101.51 | 2021-2023 | Hawkone, Acist Rxi System |
| Boston Scientific Corporation | $66.79 | 2019-2025 | Bodyguardian |
| Medtronic Vascular, INC. | $61.11 | 2019 | |
| Esperion Therapeutics, INC. | $58.83 | 2021-2022 | |
| Amgen INC. | $47.05 | 2021-2025 | Repatha, Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $47.03 | 2020-2025 | |
| Cvrx, INC. | $45.66 | 2023 | Barostim Neo System |
| Heartflow, INC. | $43.87 | 2025 | |
| Daiichi Sankyo INC. | $38.47 | 2022-2023 | Injectafer |
| Inspire Medical Systems, INC. | $35.23 | 2025 | Inspire |
| Edwards Lifesciences Corporation | $28.44 | 2023 | |
| Gilead Sciences, INC. | $25.65 | 2019 | |
| Sanofi-Aventis U.S. LLC | $20.60 | 2023 | |
| Scpharmaceuticals INC. | $18.52 | 2024 | |
| Astellas Pharma US INC | $17.74 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $15.56 | 2019 | |
| Cardiovascular Systems INC. | $14.92 | 2019 | |
| Novo Nordisk INC | $14.75 | 2024 | Ozempic |
| Amarin Pharma, INC. | $11.65 | 2020 | |
| Irhythm Technologies, INC. | $11.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Eichholz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.